An investigation of the interaction between halofantrine, CYP2D6 and CYP3A4: studies with human liver microsomes and heterologous enzyme expression systems.

No abstract is available for this paper.

• Publication year

  1995

• Venue

  British Journal of Clinical Pharmacology

• Publication date

  1995-10-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1111/J.1365-2125.1995.TB04559.XPMID 8554939PMCID PMC1365156
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Lounging in a lysosome: the intracellular lifestyle of Coxiella burnetii

  2007cited by this paper
• Plasma concentrations of the enantiomers of halofantrine and its main metabolite in malaria patients

  2004cited by this paper
• Determination of human hepatic cytochrome P4501A2 activity in vitro use of tacrine as an isoenzyme-specific probe.

  1995cited by this paper
• Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes.

  1994cited by this paper
• Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians.

  1994cited by this paper
• Selective inhibitors of cytochromes P450.

  1994cited by this paper
• Pharmacogenetic Phenotyping and Genotyping

  1994cited by this paper
• Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: molecular modeling and inhibition studies.

  1993cited by this paper
• Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine

  1993cited by this paper
• Analysis of imipramine and three metabolites produced by isozyme CYP2D6 expressed in a human cell line.

  1993cited by this paper
• The pharmacogenetics of the selective serotonin reuptake inhibitors

  1993cited by this paper
• Molecular heterogeneity of the XbaI defined 44kb allele of the CYP2D locus within the Caucasian population.

  1993cited by this paper
• Cardiac effects of antimalarial treatment with halofantrine.

  1993cited by this paper
• Cardiac effect of halofantrine.

  1993cited by this paper
• Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolism.

  1993cited by this paper
• Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline.

  1993cited by this paper
• A preliminary 3D model for cytochrome P450 2D6 constructed by homology model building

  1993cited by this paper
• Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease.

  1992cited by this paper
• Halofantrine

  1992cited by this paper
• A predictive model for substrates of cytochrome P450-debrisoquine (2D6).

  1992cited by this paper
• Comparison of urinary 6‐β‐cortisol and the erythromycin breath test as measures of hepatic P450IIIA (CYP3A) activity

  1992cited by this paper
• Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes.

  1992cited by this paper
• The human hepatic cytochromes P450 involved in drug metabolism.

  1992cited by this paper
• Comparison of SPECT applications in neurology and psychiatry.

  1992cited by this paper
• Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes.

  1992cited by this paper
• Relative expression of cytochrome P450 isoenzymes in human liver and association with the metabolism of drugs and xenobiotics.

  1992cited by this paper
• In vitro activity of the enantiomers of mefloquine, halofantrine and enpiroline against Plasmodium falciparum.

  1992cited by this paper
• Human cytochromes P450: problems and prospects.

  1992cited by this paper
• Measurement of halofantrine and its major metabolite desbutylhalofantrine in plasma and blood by high-performance liquid chromatography: a new methodology.

  1992cited by this paper
• Bufuralol, dextromethorphan, and debrisoquine as prototype substrates for human P450IID6.

  1991cited by this paper
• Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P-450 IIIA4.

  1991cited by this paper
• Molecular genetics of the debrisoquin‐sparteine polymorphism

  1991cited by this paper
• A dose-effect study of the in vivo inhibitory effect of quinidine on sparteine oxidation in man.

  1990cited by this paper
• Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes.

  1990cited by this paper
• Metabolism of the contraceptive steroid desogestrel by human liver in vitro.

  1990cited by this paper
• Human pharmacokinetics of halofantrine hydrochloride

  1989cited by this paper
• Determination of halofantrine and its principal metabolite desbutylhalofantrine in biological fluids by reversed-phase high-performance liquid chromatography.

  1988cited by this paper
• High-performance liquid chromatographic assays for bufuralol 1'-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver.

  1987cited by this paper
• Extensive metabolizers of debrisoquine become poor metabolizers during quinidine treatment.

  1987cited by this paper
• Immunoblotting and dot immunobinding--current status and outlook.

  1984cited by this paper
• Competitive inhibition of sparteine oxidation in human liver by beta-adrenoceptor antagonists and other cardiovascular drugs.

  1984cited by this paper
• Evaluation of the antimalarial activity of the phenanthrenemethanol halofantrine (WR 171,669).

  1982cited by this paper
• Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4

  1970cited by this paper
• THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE.

  1964cited by this paper
• Protein measurement with the Folin phenol reagent.

  1951cited by this paper

• Metabolism and Interactions of Chloroquine and Hydroxychloroquine with Human Cytochrome P450 Enzymes and Drug Transporters.

  2020cites this paper
• A Cytochrome 450 Interaction of Chloroquine with Second Generation Antipsychotics

  2017cites this paper
• Inhibitory and inductive effects of Phikud Navakot extract on human cytochrome P450.

  2016cites this paper
• Antimalarial metabolization: what have we learnt so far?

  2015cites this paper
• Computational predictions of the site of metabolism of cytochrome P450 2D6 substrates: comparative analysis, molecular docking, bioactivation and toxicological implications

  2015cites this paper
• Design and applications of bioprecursors: a retrometabolic approach.

  2014cites this paper
• Effect of Single Nucleotide Polymorphisms in Cytochrome P450 Isoenzyme and N-Acetyltransferase 2 Genes on the Metabolism of Artemisinin-Based Combination Therapies in Malaria Patients from Cambodia and Tanzania

  2012cites this paper
• Ligand- and protein-based modeling studies of the inhibitors of human cytochrome P450 2D6 and a virtual screening for potential inhibitors from the Chinese herbal medicine, Scutellaria baicalensis (Huangqin,Baikal Skullcap).

  2012cites this paper
• Toward reduction in animal sacrifice for drugs: Molecular modeling of Macaca fascicularis P450 2C20 for virtual screening of Homo sapiens P450 2C8 substrates

  2012cites this paper
• Effect of serum lipoproteins on stereoselective halofantrine metabolism by rat hepatocytes.

  2012cites this paper
• The effect of oral lipids and lipoproteins on the biodistribution, metabolism and electrocardiographic side-effects of halofantrine

  2011cites this paper
• Agents Active against Parasites and Pneumocystis

  2010cites this paper
• Coprescription of tamoxifen and medications that inhibit CYP2D6.

  2010cites this paper
• Human CYP2C8: structure, substrate specificity, inhibitor selectivity, inducers and polymorphisms.

  2009cites this paper
• The effects of pharmacogenetics on pharmacokinetics of artemisinin-based combinations in malaria patients

  2009cites this paper
• Haemolytic effects and changes in serum enzymes in normal rats exposed to halofantrine hydrochloride overdose.

  2009cites this paper
• Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance

  2009cites this paper
• New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme

  2009cites this paper
• Substrate specificity, inhibitors and regulation of human cytochrome P450 2D6 and implications in drug development.

  2009cites this paper
• A microarray-based system for the simultaneous analysis of single nucleotide polymorphisms in human genes involved in the metabolism of anti-malarial drugs

  2009cites this paper
• Effect of fluconazole on the pharmacokinetics of halofantrine in healthy volunteers

  2009cites this paper
• The stereoselective metabolism of halofantrine to desbutylhalofantrine in the rat: evidence of tissue-specific enantioselectivity in microsomal metabolism.

  2007cites this paper
• PHARMACOGENETICS OF CYP2D6: CLINICAL IMPLICATIONS IN PSYCHIATRIC PATIENTS TREATED WITH ANTIPSYCHOTIC DRUGS

  2007cites this paper
• Effects of Prior Administration of Amodiaquine on the Disposition of Halofantrine in Healthy Volunteers

  2007influential citation
• Drug–drug interactions in the metabolism of imidafenacin: Role of the human cytochrome P450 enzymes and UDP-glucuronic acid transferases, and potential of imidafenacin to inhibit human cytochrome P450 enzymes

  2007cites this paper
• AN EXAMINATION OF THE INTERPLAY BETWEEN ENTEROCYTE-BASED METABOLISM AND LYMPHATIC DRUG TRANSPORT IN THE RAT

  2006cites this paper
• Clinical implications of CYP2D6 genetic polymorphism during treatment with antipsychotic drugs.

  2006cites this paper
• Pharmacogenetics of cytochromes P450 in tropical medicine.

  2006cites this paper
• Les inhibiteurs "suicides" des Cytochromes P450: Etablissement d'une banque de données, mise au point d'un test de screening et étudesstructures-activité concernant des substrats furaniques du CYP 3A4.

  2005cites this paper
• Antimalarial drugs: QT prolongation and cardiac arrhythmias

  2005cites this paper
• Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors

  2004influential citation
• Effects of tetracycline on the pharmacokinetics of halofantrine in healthy volunteers.

  2004cites this paper
• Estudio del citocromo CYP2C9 en la población española: Implicación en el metabolismo de fármacos en voluntarios sanos y en pacientes psiquiátricos

  2003cites this paper
• Use of Robust Classification Techniques for the Prediction of Human Cytochrome P450 2D6 Inhibition

  2003cites this paper
• In vitro metabolism of chloroquine: identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation.

  2003cites this paper
• Does stereoselective lymphatic absorption contribute to the enantioselective pharmacokinetics of halofantrine In Vivo?

  2003cites this paper
• Characteristics of cytochrome P450-catalysed drug metabolism with focus on a black Tanzanian population

  2003cites this paper
• Pharmacokinetic and pharmacodynamic interaction between grapefruit juice and halofantrine

  2002cites this paper
• Summary of information on human CYP enzymes: human P450 metabolism data

  2002cites this paper
• Potentiation of halofantrine‐induced QTc prolongation by mefloquine: correlation with blood concentrations of halofantrine

  2001cites this paper
• Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation.

  2001cites this paper
• In Vitro Evaluation of Drug Interaction Caused by Enzyme Inhibition —HAB Protocol—

  2001cites this paper
• Potent inhibition of CYP2D6 by haloperidol metabolites: stereoselective inhibition by reduced haloperidol.

  2001cites this paper
• A conscious dog model for assessing the absorption, enterocyte-based metabolism, and intestinal lymphatic transport of halofantrine.

  2001cites this paper
• Effect of three structurally related antimalarial drugs on liver microsomal components and lipid peroxidation in rats.

  2000cites this paper
• Pharmacokinetics of Artemisinin-Type Compounds

  2000cites this paper
• Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A.

  2000influential citation
• Clinical Pharmacokinetics of Artemether and Lumefantrine (Riamet®)

  1999cites this paper
• In vitro effects of racemates, separate enantiomers and major metabolites of mefloquine and halofantrine on metoprolol biotransformation by rat liver microsomes.

  1999cites this paper
• Metabolism of artelinic acid to dihydroqinqhaosu by human liver cytochrome P4503A.

  1999cites this paper
• Improved reliability of the rapid microtiter plate assay using recombinant enzyme in predicting CYP2D6 inhibition in human liver microsomes.

  1999cites this paper
• Cytochrome P-450-mediated metabolism of the individual enantiomers of the antidepressant agent reboxetine in human liver microsomes.

  1999cites this paper
• Halofantrine Metabolism in Microsomes in Man: Major Role of CYP 3A4 and CYP 3A5

  1999influential citation
• Les antimalariques: pharmacologie, pharmacocintique et toxicit chez l'adulte

  1999cites this paper
• Fully automated analysis of activities catalysed by the major human liver cytochrome P450 (CYP) enzymes: assessment of human CYP inhibition potential.

  1999cites this paper
• Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6.

  1999cites this paper
• Effect of selected antimalarial drugs and inhibitors of cytochrome P-450 3A4 on halofantrine metabolism by human liver microsomes.

  1999cites this paper
• Inhibition and induction of human cytochrome P450 (CYP) enzymes.

  1998cites this paper
• Chiral chromatographic method to determine the enantiomers of halofantrine and its main chiral desbutyl metabolite in erythrocytes.

  1998cites this paper
• Identification and Characterization of Human Cytochrome P 450 Isoforms Interacting with Pimozide 1

  1998cites this paper
• Validation of a rapid microtiter plate assay to conduct cytochrome P450 2D6 enzyme inhibition studies

  1998cites this paper
• Metabolism of halofantrine to its equipotent metabolite, desbutylhalofantrine, is decreased when orally administered with ketoconazole.

  1998cites this paper
• Interaction of terfenadine and its primary metabolites with cytochrome P450 2D6.

  1998cites this paper
• Metabolism of beta-arteether to dihydroqinghaosu by human liver microsomes and recombinant cytochrome P450.

  1998cites this paper
• Identification and characterization of human cytochrome P450 isoforms interacting with pimozide.

  1998cites this paper
• Formulation design and bioavailability assessment of lipidic self-emulsifying formulations of halofantrine

  1998cites this paper
• Halofantrine and chloroquine inhibit CYP2D6 activity in healthy Zambians.

  1998cites this paper
• Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms.

  1997cites this paper
• Rapid and simple method to determine chloroquine and its desethylated metabolites in human microsomes by high-performance liquid chromatography with fluorescence detection.

  1997cites this paper
• Genetic polymorphism of drug metabolising enzymes in African populations: implications for the use of neuroleptics and antidepressants.

  1997cites this paper
• Clinical Pharmacokinetics and Metabolism of Chloroquine

  1996cites this paper
• Pharmacokinetics of Quinine, Chloroquine and Amodiaquine

  1996cites this paper
• N-Hydroxylation of dapsone by multiple enzymes of cytochrome P450: implications for inhibition of haemotoxicity.

  1995cites this paper